[Specific antifungal treatment in patients with neutropenia and fever: current status of the fungicidal activity of caspofungin].
Candidiasis and aspergillosis are the most frequent mycosis in patients with febrile neutropenia. Other infections caused by emergent yeast-like organisms, such as hyalohyphomycosis, Fusarium disease and scedosporiosis, phaeohyphomycosis (caused by pigmented mycelia) and zygomycosis are becoming more frequent. The management of documented fungal infections should consider several aspects, such as clinical patterns, the patient's clinical condition, the species involved, in vitro sensitivity and the suitable treatment duration, apart from the selection of the drug and suggested regimen. Though new drugs have been developed, the therapeutic armory is still very limited. Combined treatments are promising, but their use is not yet standardized.
Finquelievich
J
J
Departamento de Microbiologia, Universidad de Buenos Aires, Republica Argentina.
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000517:prevention & control; D002177:Candidiasis / Q000150:complications / Q000517:prevention & control; D000077336:Caspofungin; D054714:Echinocandins / Q000627:therapeutic use*; D005334:Fever / Q000150:complications*; D006801:Humans; D055666:Lipopeptides; D009181:Mycoses / Q000150:complications / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications*; D020096:Zygomycosis / Q000150:complications / Q000517:prevention & control
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin